Compass Therapeutics, Inc. (CMPX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Compass Therapeutics, Inc. in 2026. The next earnings report is expected on November 11, 2026.
Compass Therapeutics missed consensus estimates on EPS, posting EPS of $-0.13 versus an estimate of $-0.1107, and beat on revenue with $0 reported, exceeding the estimate by 100.0%. In the prior quarter, EPS also missed expectations while revenue came in ahead of estimates.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
